<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820764</url>
  </required_header>
  <id_info>
    <org_study_id>10228</org_study_id>
    <nct_id>NCT04820764</nct_id>
  </id_info>
  <brief_title>EFS of the CardioMech MVRS</brief_title>
  <official_title>Early Feasibility Study of the CardioMech Mitral Valve Repair System (MVRS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioMech AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioMech AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and performance evaluation of the CardioMech Mitral Valve Repair System (MVRS) in&#xD;
      patients with degenerative mitral valve regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the clinical study is to obtain clinical data on the CardioMech Mitral Valve&#xD;
      Repair System (MVRS) in patients diagnosed with moderate to severe (≥3+) or severe (≥4+),&#xD;
      symptomatic, degenerative mitral regurgitation and who are determined to be at intermediate&#xD;
      or high surgical risk for mitral valve repair, as assessed by the site's multidisciplinary&#xD;
      heart team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from serious adverse events determined to be related to the CardioMech MVRS device or procedure</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MR grade</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>CardioMech Mitral Valve Repair System (MVRS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioMech MVRS</intervention_name>
    <description>CardioMech MVRS</description>
    <arm_group_label>CardioMech Mitral Valve Repair System (MVRS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eighteen (18) years of age or greater&#xD;
&#xD;
          -  Moderate to severe (≥3+) or severe (≥4+) mitral valve regurgitation (per American&#xD;
             Society of Echocardiography (ASE) guidelines) due to mitral valve prolapse or flail&#xD;
&#xD;
          -  Intermediate or high surgical risk for mitral valve repair&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of rheumatic heart disease&#xD;
&#xD;
          -  History of prior endocarditis&#xD;
&#xD;
          -  History of prior repair or replacement of the mitral valve, annuloplasty or&#xD;
             valvuloplasty or has a left atrial appendage closure device&#xD;
&#xD;
          -  Severely calcified mitral leaflet or has evidence of calcification in the grasping&#xD;
             area of the leaflets that would prevent leaflet anchor positioning and deployment&#xD;
&#xD;
          -  Complex mechanism of MR (leaflet perforation, severe leaflet calcifications,&#xD;
             commissural extension, commissural prolapse, multiple flail or prolapsing segments,&#xD;
             cleft) present on required imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathew Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mayra Guerrero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Feist</last_name>
    <phone>612.787.5386</phone>
    <email>Nikki.Feist@cardiomech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ascension St. Francis via Christi</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Thunberg, RN, BSN</last_name>
      <email>Meredith.thunberg@cckheart.com</email>
    </contact>
    <investigator>
      <last_name>Bassem Chehab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Konwinski, MS, CCRC</last_name>
      <email>Konwinski.craig@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mayra Guerrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Querijero</last_name>
      <email>Michael.Querijero@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Mathew Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health Sanger Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Amaro, MS, RN</last_name>
    </contact>
    <investigator>
      <last_name>Michael Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. Thomas West</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelio Rodriguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Evelio Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Morse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrianna Robison, MS</last_name>
      <email>Adrianna.Robison@imail.org</email>
    </contact>
    <investigator>
      <last_name>Brian Whisenant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

